Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update

References

• Frieri G, Giacomelli R, Pimpo M et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut47(3), 410–414 (2000).
   PubMed Web of Science ®Google Scholar
• Malaty HM, Fan X, Opekun AR, Thibodeaux C, Ferry GD. Rising incidence of inflammatory bowel disease among children: a 12-year study. J. Pediatr. Gastroenterol. Nutr.50(1), 27–31 (2010).
   PubMed Web of Science ®Google Scholar
• Turunen P, Kolho K, Auvinen A, Iltanen S, Huhtala H, Ashorn M. Incidence of inflammatory bowel disease in Finnish children, 1987–2003. Inflamm. Bowel Dis.12(8), 677–683 (2006).
   PubMed Web of Science ®Google Scholar
• Vind I, Riis L, Jess T et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database. Am. J. Gastroenterol.101(6), 1274–1282 (2006).
   PubMed Web of Science ®Google Scholar
• Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr.44(2), 265–267 (2007).
   PubMed Web of Science ®Google Scholar
• Friend DR. New oral delivery systems for treatment of inflammatory bowel disease. Adv. Drug Deliv. Rev.57(2), 247–265 (2005).
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Zimmermann E. Novel drug delivery strategies for the treatment of inflammatory bowel disease. Expert Opin. Drug Deliv.2(3), 451–463 (2005).
   PubMedGoogle Scholar
• Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv. Drug Deliv. Rev.57(2), 267–279 (2005).
   PubMed Web of Science ®Google Scholar
• Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am. J. Gastroenterol.95(7), 1628–1636 (2000).
   PubMed Web of Science ®Google Scholar
• Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F. Treatment of perianal fistulas in Crohn’s disease by local injection of antibody to TNF-α accounts for a favourable clinical response in selected cases: a pilot study. Scand. J. Gastroenterol.41(9), 1064–1072 (2006).
   PubMed Web of Science ®Google Scholar
• Lichtiger S. Healing of perianal fistulae by local injection of antibody to TNF. Gastroenterology120(5), A621 (2001).
   Google Scholar
• Kagan L, Hoffman A. Systems for region selective drug delivery in the gastrointestinal tract: biopharmaceutical considerations. Expert Opin. Drug Deliv.5(6), 681–692 (2008).
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Drug targeting. Eur. J. Pharm. Sci.11(Suppl. 2), S81–S91 (2000).
   PubMed Web of Science ®Google Scholar
• Van den Mooter G. Colon drug delivery. Expert Opin. Drug Deliv.3(1), 111–125 (2006).
   PubMedGoogle Scholar
• Sinha VR, Kumria R. Colonic drug delivery: prodrug approach. Pharm. Res.18(5), 557–564 (2001).
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv. Drug Deliv. Rev.57(2), 303–316 (2005).
   PubMed Web of Science ®Google Scholar
• Hofer KN. Oral budesonide in the management of Crohn’s disease. Ann. Pharmacother.37(10), 1457–1464 (2003).
   PubMed Web of Science ®Google Scholar
• Kumana C, Seaton T, Meghji M, Castelli M, Benson R, Sivakumaran T. Beclomethasone dipropionate enemas for treating inflammatory bowel disease without producing Cushing’s syndrome or hypothalamic pituitary adrenal suppression. Lancet13(1), 579–583 (1982).
   Google Scholar
• Rhodes J, Robinson R, Beales I et al. Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis. Aliment. Pharmacol. Ther.27(3), 228–240 (2008).
   PubMed Web of Science ®Google Scholar
• Rubinstein A. Microbially controlled drug delivery to the colon. Biopharm. Drug Dispos.11(6), 465–475 (1990).
   PubMed Web of Science ®Google Scholar
• Youngberg C, Berardi R, Howatt W et al. Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects. Dig. Dis. Sci.32(5), 472–480 (1987).
   PubMed Web of Science ®Google Scholar
• Leopold C, Eikeler D. Eudragit® E as coating material for the pH-controlled drug release in the topical treatment of inflammatory bowel disease (IBD). J. Drug Target.6(2), 85–94 (1998).
   PubMed Web of Science ®Google Scholar
• Meissner Y, Pellequer Y, Lamprecht A. Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery. Int. J. Pharm.316(1–2), 138–143 (2006).
   PubMed Web of Science ®Google Scholar
• Rudolph MW, Klein S, Beckert TE, Petereit H-U, Dressman JB. A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur. J. Pharm. Biopharm.51(3), 183–190 (2001).
   PubMed Web of Science ®Google Scholar
• Haupt S, Rubinstein A. The colon as a possible target for orally administered peptide and protein drugs. Crit. Rev. Ther. Drug Carrier. Syst.19(6), 499–451 (2002).
   PubMed Web of Science ®Google Scholar
• Kumar P, Mishra B. Colon targeted drug delivery systems – an overview. Curr. Drug Deliv.5(3), 186–198 (2008).
   PubMedGoogle Scholar
• Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut27(8), 886–892 (1986).
   PubMed Web of Science ®Google Scholar
• Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm.186(2), 119–125 (1999).
   PubMed Web of Science ®Google Scholar
• Yu LX, Crison JR, Amidon GL. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int. J. Pharm.140(1), 111–118 (1996).
   Web of Science ®Google Scholar
• Gazzaniga A, Maroni A, Sangalli M, Zema L. Time-controlled oral delivery systems for colon targeting. Expert Opin. Drug Deliv.3(5), 583–597 (2006).
   PubMedGoogle Scholar
• Maroni A, Zema L, Cerea M, Sangalli M. Oral pulsatile drug delivery systems. Expert Opin. Drug Deliv.2(5), 855–871 (2005).
   PubMedGoogle Scholar
• Hu Z, Kimura G, Ito Y et al. Technology to obtain sustained release characteristics of drugs after delivered to the colon. J. Drug Target.6(6), 439–448 (1999).
   PubMed Web of Science ®Google Scholar
• Jeong Y-I, Ohno T, Hu Z et al. Evaluation of an intestinal pressure-controlled colon delivery capsules prepared by a dipping method. J. Control. Release71(2), 175–182 (2001).
   PubMed Web of Science ®Google Scholar
• Chourasia M, Jain S. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci.6(1), 33–66 (2003).
   PubMed Web of Science ®Google Scholar
• Jain S, Jain A. Target-specific drug release to the colon. Expert Opin. Drug Deliv.5(5), 483–498 (2008).
   PubMed Web of Science ®Google Scholar
• Fiorino G, Fries W, De La Rue S, Malesci A, Repici A, Danese S. New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. Curr. Med. Chem.17(17), 1851–1857 (2010).
   PubMed Web of Science ®Google Scholar
• Kale-Pradhan PB, Pradhan RS, Wilhelm SM. Multi-matrix system mesalamine: to use or not to use. Ann. Pharmacother.42(2), 265–269 (2008).
   PubMedGoogle Scholar
• Kamm MA, Lichtenstein GR, Sandborn WJ et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm. Bowel Dis.15(1), 1–8 (2009).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn‘s disease: the ACCENT I randomised trial. Lancet359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology128(4), 862–869 (2005).
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med.340(18), 1398–1405 (1999).
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med.350(9), 876–885 (2004).
   PubMed Web of Science ®Google Scholar
• Shteyer E, Wilschanski M. Novel therapeutic modalities in pediatric inflammatory bowel disease. Isr. Med. Assoc. J.10(11), 816–820 (2008).
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJH et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N. Engl. J. Med.337(15), 1029–1036 (1997).
   PubMed Web of Science ®Google Scholar
• Bosani M, Ardizzone S, Porro G. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics3, 77–97 (2009).
   PubMedGoogle Scholar
• Rutgeerts P, van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology126(6), 1593–1610 (2004).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology136(4), 1182–1197 (2009).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med.353(18), 1912–1925 (2005).
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE trial. Gastroenterology132(5), 1672–1683 (2007).
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med.353(4), 362–368 (2005).
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs65(16), 2253–2286 (2005).
   PubMed Web of Science ®Google Scholar
• Nakamura K, Honda K, Mizutani T, Akiho H, Harada N. Novel strategies for the treatment of inflammatory bowel disease: selective inhibition of cytokines and adhesion molecules. World J. Gastroenterol.12(29), 4628–4635 (2006).
   PubMed Web of Science ®Google Scholar
• Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol.3(7), 521–533 (2003).
   PubMed Web of Science ®Google Scholar
• Braus NA, Elliott DE. Advances in the pathogenesis and treatment of IBD. Clin. Immunol.132(1), 1–9 (2009).
   PubMed Web of Science ®Google Scholar
• Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol.8(6), 458–466 (2008).
   PubMed Web of Science ®Google Scholar
• Wirtz S, Neurath MF. Gene transfer approaches for the treatment of inflammatory bowel disease. Gene Ther.10(10), 854–860 (2003).
   PubMed Web of Science ®Google Scholar
• Atreya R, Mudter J, Finotto S et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med.6(5), 583–588 (2000).
   PubMed Web of Science ®Google Scholar
• Pickles RJ, Fahrner JA, Petrella JM, Boucher RC, Bergelson JM. Retargeting the coxsackievirus and adenovirus receptor to the apical surface of polarized epithelial cells reveals the glycocalyx as a barrier to adenovirus-mediated gene transfer. J. Virol.74(13), 6050–6057 (2000).
   PubMed Web of Science ®Google Scholar
• Barbara G, Xing Z, Hogaboam CM, Gauldie J, Collins SM. Interleukin 10 gene transfer prevents experimental colitis in rats. Gut46(3), 344–349 (2000).
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Chamberlain JR, Schmiedlin-Ren P et al. Chimeric Ad5 vectors expressing the short fiber of Ad41 show reduced affinity for human intestinal epithelium. Mol. Pharm.2(6), 500–508 (2005).
   PubMedGoogle Scholar
• Kesisoglou F, Schmiedlin-Ren P, Fleisher D, Roessler B, Zimmermann EM. Restituting intestinal epithelial cells exhibit increased transducibility by adenoviral vectors. J. Gene Med.8(12), 1379–1392 (2006).
   PubMedGoogle Scholar
• Sasaki M, Mathis JM, Jennings M et al. Reversal of experimental colitis disease activity in mice following administration of an adenoviral IL-10 vector. J. Inflamm.2(1), 13 (2005).
   Google Scholar
• Schmiedlin-Ren P, Kesisoglou F, Mapili J et al. Increased transduction of human intestinal epithelial cells by adenoviral vectors in inflammatory bowel disease. Inflamm. Bowel Dis.11(5), 464–472 (2005).
   PubMedGoogle Scholar
• Elinav E, Adam N, Waks T, Eshhar Z. Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology136(5), 1721–1731 (2009).
   PubMed Web of Science ®Google Scholar
• Wang L, Cheng C, Ko S-Y et al. Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity. J. Virol.83(14), 7166–7175 (2009).
   PubMedGoogle Scholar
• Seppen J, Barry SC, Klinkspoor JH et al. Apical gene transfer into quiescent human and canine polarized intestinal epithelial cells by lentivirus vectors. J. Virol.74(16), 7642–7645 (2000).
   PubMedGoogle Scholar
• During MJ, Xu R, Young D, Kaplitt MG, Sherwin RS, Leone P. Peroral gene therapy of lactose intolerance using an adeno-associated virus vector. Nat. Med.4(10), 1131–1135 (1998).
   PubMed Web of Science ®Google Scholar
• Polyak S, Mah C, Porvasnik S et al. Gene delivery to intestinal epithelial cells in vitro and in vivo with recombinant adeno-associated virus types 1, 2 and 5. Dig. Dis. Sci.53(5), 1261–1270 (2008).
   PubMed Web of Science ®Google Scholar
• Rogy M, Beinhauer B, Reinisch W, Huang L, Pokieser P. Transfer of interleukin-4 and interleukin-10 in patients with severe inflammatory bowel disease of the rectum. Hum. Gene Ther.11(12), 1731–1741 (2000).
   PubMed Web of Science ®Google Scholar
• Nakase H, Okazaki K, Tabata Y, Chiba T. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease. J. Gastroenterol.38(15), 59–62 (2003).
   PubMed Web of Science ®Google Scholar
• Nakase H, Okazaki K, Tabata Y et al. Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J. Pharmacol. Exp. Ther.292(1), 15–21 (2000).
   PubMed Web of Science ®Google Scholar
• Tabata Y, Inoue Y, Ikada Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine14(17–18), 1677–1685 (1996).
   PubMed Web of Science ®Google Scholar
• Huang Y, Leobandung W, Foss A, Peppas NA. Molecular aspects of muco- and bioadhesion: tethered structures and site-specific surfaces. J. Control. Release65(1–2), 63–71 (2000).
   PubMed Web of Science ®Google Scholar
• Meissner Y, Lamprecht A. Alternative drug delivery approaches for the therapy of inflammatory bowel disease. J. Pharm. Sci.97(8), 2878–2891 (2008).
   PubMed Web of Science ®Google Scholar
• Serra L, Doménech J, Peppas NA. Engineering design and molecular dynamics of mucoadhesive drug delivery systems as targeting agents. Eur. J. Pharm. Biopharm.71(3), 519–528 (2009).
   PubMed Web of Science ®Google Scholar
• McGuckin MA, Eri R, Simms LA, Florin TH, Radford-Smith G. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm. Bowel Dis.15(1), 100–113 (2009).
   PubMed Web of Science ®Google Scholar
• Laukoetter M, Nava P, Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. World J. Gastroenterol.14(3), 401–407 (2008).
   PubMed Web of Science ®Google Scholar
• Nakase H, Okazaki K, Tabata Y et al. New cytokine delivery system using gelatin microspheres containing interleukin-10 for experimental inflammatory bowel disease. J. Pharmacol. Exp. Ther.301(1), 59–65 (2002).
   PubMed Web of Science ®Google Scholar
• Nakase H, Okazaki K, Tabata Y et al. An oral drug delivery system targeting immune-regulating cells ameliorates mucosal injury in trinitrobenzene sulfonic acid-induced colitis. J. Pharmacol. Exp. Ther.297(3), 1122–1128 (2001).
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Ubrich N, Yamamoto H et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther.299(2), 775–781 (2001).
   PubMed Web of Science ®Google Scholar
• Makhlof A, Tozuka Y, Takeuchi H. pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model. Eur. J. Pharm. Biopharm.72(1), 1–8 (2009).
   PubMed Web of Science ®Google Scholar
• Hassani S, Pellequer Y, Lamprecht A. Selective adhesion of nanoparticles to inflamed tissue in gastric ulcers. Pharm. Res.26(5), 1149–1154 (2009).
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Schafer U, Lehr C. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm. Res.18(6), 788–793 (2001).
   PubMed Web of Science ®Google Scholar
• Bravo-Osuna I, Vauthier C, Farabollini A, Palmieri GF, Ponchel G. Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials28(13), 2233–2243 (2007).
   PubMed Web of Science ®Google Scholar
• Tirosh B, Rubinstein A. Migration of adhesive and nonadhesive particles in the rat intestine under altered mucus secretion conditions. J. Pharm. Sci.87(4), 453–456 (1998).
   PubMed Web of Science ®Google Scholar
• Jubeh TT, Antler S, Haupt S, Barenholz Y, Rubinstein A. Local prevention of oxidative stress in the intestinal epithelium of the rat by adhesive liposomes of superoxide dismutase and tempamine. Mol. Pharm.2(1), 2–11 (2005).
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Zhou S, Niemiec S, Lee J, Zimmermann E, Fleisher D. Liposomal formulations of inflammatory bowel disease drugs: local versus systemic drug delivery in a rat model. Pharm. Res.22(8), 1320–1330 (2005).
   PubMed Web of Science ®Google Scholar
• Jubeh T, Barenholz Y, Rubinstein A. Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes. Pharm. Res.21(3), 447–453 (2004).
   PubMed Web of Science ®Google Scholar
• Tirosh B, Khatib N, Barenholz Y, Nissan A, Rubinstein A. Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa. Mol. Pharm.6(4), 1083–1091 (2009).
   PubMed Web of Science ®Google Scholar
• Lehr C, Bouwstra J, Kok W, Noach A, de Boer A, Junginger H. Bioadhesion by means of specific binding of tomato lectin. Pharm. Res.9(4), 547–553 (1992).
   PubMed Web of Science ®Google Scholar
• Irache J, Durrer C, Duchene D, Ponchel G. Bioadhesion of lectin-latex conjugates to rat intestinal mucosa. Pharm. Res.13(11), 1716–1719 (2000).
   Google Scholar
• Bies C, Lehr C-M, Woodley JF. Lectin-mediated drug targeting: history and applications. Adv. Drug Deliv. Rev.56(4), 425–435 (2004).
   PubMed Web of Science ®Google Scholar
• Gabor F, Bogner E, Weissenboeck A, Wirth M. The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv. Drug Deliv. Rev.56(4), 459–480 (2004).
   PubMed Web of Science ®Google Scholar
• Sakhalkar HS, Dalal MK, Salem AK et al. Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc. Natl Acad. Sci. USA100(26), 15895–15900 (2003).
   PubMed Web of Science ®Google Scholar
• Sakhalkar HS, Hanes J, Fu J et al. Enhanced adhesion of ligand-conjugated biodegradable particles to colitic venules. FASEB J.19(7), 792–794 (2005).
   PubMed Web of Science ®Google Scholar
• Fedorak R, Madsen K. Probiotics and the management of inflammatory bowel disease. Inflamm. Bowel Dis.10(3), 286–299 (2004).
   PubMed Web of Science ®Google Scholar
• Heilpern D, Szilagyi A. Manipulation of intestinal microbial flora for therapeutic benefit in inflammatory bowel diseases: review of clinical trials of probiotics, pre-biotics and synbiotics. Rev. Recent Clin. Trials3(3), 167–184 (2008).
   PubMedGoogle Scholar
• Isaacs K, Herfarth H. Role of probiotic therapy in IBD. Inflamm. Bowel Dis.14(11), 1597–1605 (2008).
   PubMed Web of Science ®Google Scholar
• Steidler L, Hans W, Schotte L et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science289(5483), 1352–1355 (2000).
   PubMed Web of Science ®Google Scholar
• Steidler L, Neirynck S, Huyghebaert N et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat. Biotech.21(7), 785–789 (2003).
   PubMed Web of Science ®Google Scholar
• Braat H, Rottiers P, Hommes DW et al. A Phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin. Gastroenterol. Hepatol.4(6), 754–759 (2006).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn’s disease. N. Engl. J. Med.357(3), 228–238 (2007).
   PubMed Web of Science ®Google Scholar
• Pappas D, Bathon J, Hanicq D, Yasothan U, Kirkpatrick P. Golimumab. Nat. Rev. Drug Discov.8(9), 695–696 (2009).
   PubMed Web of Science ®Google Scholar
• Chang J, Lichtenstein G. Drug insight: antagonists of tumor-necrosis factor-a in the treatment of inflammatory bowel disease. Nat. Clin. Pract. Gastroenterol. Hepatol.3(4), 220–228 (2006).
   PubMedGoogle Scholar
• Soler D, Chapman T, Yang L-L, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. J. Pharmacol. Exp. Ther.330(3), 864–875 (2009).
   PubMed Web of Science ®Google Scholar
• Pullen N, Molloy E, Carter D et al. Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. Br. J. Pharmacol.157(2), 281–293 (2009).
   PubMed Web of Science ®Google Scholar
• Shanahan WJ. ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1. Expert. Opin. Investig. Drugs8(9), 1417–1429 (1999).
   PubMedGoogle Scholar
• Sandborn W. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn’s disease. Rev. Gastroenterol. Disord.4(3), S25–S33 (2004).
   PubMedGoogle Scholar
• Sandborn WJ, Feagan BG, Fedorak RN et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology135(4), 1130–1141 (2008).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat. Clin. Pract. Rheumatol.2(11), 619–626 (2006).
   PubMedGoogle Scholar
• Price M, Probert C, Creed T. Basiliximab and infliximab for the treatment of steroid-refractory Crohn’s disease. Am. J. Gastroenterol.103(10), 2665 (2008).
   PubMedGoogle Scholar
• Hommes DW, Mikhajlova TL, Stoinov S et al. Fontolizumab, a humanised anti-interferon g antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease. Gut55(8), 1131–1137 (2006).
   PubMed Web of Science ®Google Scholar
• Carson KR, Focosi D, Major EO et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol.10(8), 816–824 (2009).
   PubMed Web of Science ®Google Scholar
• Kasran A, Boon L, Wortel C et al. Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn’s disease. Aliment. Pharmacol. Ther.22(2), 111–122 (2005).
   PubMed Web of Science ®Google Scholar
• Stronkhorst A, Radema S, Yong S et al. CD4 antibody treatment in patients with active Crohn’s disease: a 1 dose finding study. Gut40(3), 320–327 (1997).
   PubMed Web of Science ®Google Scholar
• Plevy S, Salzberg B, Van Assche G et al. A Phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology133(5), 1414–1422 (2007).
   PubMed Web of Science ®Google Scholar